By contrast, the down-regulation of RBM3 in HCT116 colon-cancer cells using specific siRNAs decreases cell growth in culture; this decrease is partially overcome by treatment with prostaglandin E2, a product of cyclooxygenase-2 enzyme activity. Here, RBM3 is linked to malignant colon neoplasm.